The short version
5 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Kymbee
Deflazacort · DEFLAZACORT 22.75 mg/mL · Suspension · Oral · Upsher-Smith Laboratories, LLC
NDC 00245-0813-13 · 1 BOTTLE in 1 CARTON / 13 mL in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 70710-2131-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$416.13per unit
middle half $416.13–$416.13 · 683 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $416.13
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
12%of plans cover it
tier 5 · prior auth 100% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 2 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $13,031.70 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA216992
- TE code
- AB
- Approval date
- Aug 11, 2025
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Deflazacort (Suspension)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Aucta Pharmaceuticals, Inc. | DEFLAZACORT 22.75 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Doppel Farmaceutici S.r.l. | DEFLAZACORT 22.75 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| PTC Therapeutics, Inc. | DEFLAZACORT 22.75 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | DEFLAZACORT 22.75 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Zydus Pharmaceuticals (USA) Inc. | DEFLAZACORT 22.75 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Kymbee — NDC 00245-0813-13," retrieved September 3, 2026, https://drugdashboards.com/drug/00245081313.
Free to cite with attribution — see how the data is put together.